Evexia Diagnostics adds dnalife nutrigenomic tests for U.S. clinicians

By AI, Created 2:36 PM UTC, May 26, 2026, /AGP/ – Evexia Diagnostics has partnered with dnalife to give more than 40,000 U.S. clinicians access to practitioner-grade nutrigenomic testing through Evexia’s network. The rollout includes DNA Core and DNA Gut, two advanced genetic panels meant to support more personalized, clinically actionable wellness care.

Why it matters: - The partnership expands access to advanced nutrigenomic testing for Functional and Integrative Medicine practitioners across the U.S. - More than 40,000 clinicians in Evexia’s nationwide network can now use dnalife testing through a single platform. - The addition gives practitioners another tool for precision-based, preventative and personalized care.

What happened: - Evexia Diagnostics and dnalife announced a strategic partnership on May 27, 2026. - Evexia will offer dnalife’s DNA Core and DNA Gut panels to clinicians using the Evexia platform. - The companies said the partnership is designed to help clinicians turn complex genetic data into actionable wellness strategies.

The details: - DNA Core combines testing that competitors typically split into three or four separate tests. - DNA Core covers methylation, lipid metabolism, insulin sensitivity, inflammation, oxidative stress, detoxification pathways, bone health, food sensitivities, vitamin and micronutrient metabolism, exercise response and recovery, and weight management. - DNA Core uses one dried blood spot sample and produces a single clinically designed report. - DNA Gut analyzes human genetic variants tied to five gut health pillars: motility, pathobionts, microbial metabolite production, gut barrier integrity and immune function. - DNA Gut is available as a standalone test or as an add-on to DNA Core from the same sample. - dnalife said DNA Gut can help practitioners tailor diet, supplement, probiotic and lifestyle interventions. - dnalife said the test is also useful alongside a gut microbiome test for a more complete assessment of risk and current health status. - dnalife said its reports are designed for clinical use, not direct-to-consumer testing. - The reports use evidence-based impact factors tied to peer-reviewed scientific associations and potential response to interventions. - The testing model uses convenient dried blood spot collection methods for patients. - Evexia said its laboratory network and dnalife’s platform together will broaden access to advanced genetic testing solutions in the U.S. - The partnership is aimed at supporting predictive, preventative and individualized patient care strategies. - More information is available at Evexia Diagnostics and dnalife.

Between the lines: - Evexia is using the partnership to deepen its specialty lab offering for Functional and Integrative Medicine clinicians. - dnalife is positioning its reports as practitioner tools, with education and clinical interpretation built into the product approach. - The deal also reflects growing demand for tests that connect genetic findings to specific care recommendations.

What’s next: - Clinicians in Evexia’s network can begin accessing dnalife panels through the platform. - The companies are likely to use the partnership to reach more U.S. practitioners who want genetics-informed care tools. - The collaboration could increase use of nutrigenomic testing alongside other functional medicine diagnostics.